What does it take for a drug to make Scrip's list of 10 of the worst launches of the decade? It means that a drug that was launched between 2010 and 2019 became a commercial dud – at least initially, in the first two years on the market. Maybe the drug failed to live up to expectations because the drug's maker was unprepared for the launch, the drug's safety and efficacy profile were out of balance, or the pricing and reimbursement strategy for that matter. But generally, the warning signs were in place and the drug maker simply failed to heed them early enough.
Dendreon Corp.'s hyped prostate cancer immunotherapy Provenge (sipuleucel-T) broke the cancer drug price ceiling when it launched in 2012...
